Tech Company Financing Transactions

Zucara Therapeutics Funding Round

On 4/3/2020, Zucara Therapeutics secured $21 million in Series A funding from Perceptive Advisors and private investors.

Transaction Overview

Announced On
4/3/2020
Transaction Type
Venture Equity
Amount
$21,000,000
Round
Series A
Investors

Perceptive Advisors (Lead Investor) (Chris Garabedian)

Proceeds Purpose
The proceeds from the financing will fund Phase 1 and Phase 2 clinical trials of ZT-01, Zucara's first-in-class drug candidate designed to prevent hypoglycemia in Type 1 Diabetes (T1D), a frequent, unintended consequence of insulin therapy for people with T1D and other types of insulin-dependent diabetes.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
661 University Ave. 1300
Toronto ON, M5G 0B7
Canada
Phone
Undisclosed
Email Address
Not Recorded
Overview
Zucara Therapeutics is developing the first once-daily therapeutic to prevent hypoglycemia (low blood sugar) in patients with diabetes. This pre-clinical technology is directed at regulating a hormone in the pancreas called somatostatin which in Type 1 diabetes is not properly controlled.
Profile
Zucara Therapeutics LinkedIn Company Profile
Social Media
Zucara Therapeutics Company Twitter Account
Company News
Zucara Therapeutics News
Facebook
Zucara Therapeutics on Facebook
YouTube
Zucara Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chairman
Michael Riddell
  Michael Riddell LinkedIn Profile  Michael Riddell Twitter Account  Michael Riddell News  Michael Riddell on Facebook
Chief Executive Officer
Michael Midmer
  Michael Midmer LinkedIn Profile  Michael Midmer Twitter Account  Michael Midmer News  Michael Midmer on Facebook
Chief Scientific Officer
Richard Liggins
  Richard Liggins LinkedIn Profile  Richard Liggins Twitter Account  Richard Liggins News  Richard Liggins on Facebook
VP - Regulatory Affairs
Susan Peers
  Susan Peers LinkedIn Profile  Susan Peers Twitter Account  Susan Peers News  Susan Peers on Facebook


 

 

Browse more venture capital transactions:

Prev: 4/3/2020: Concertio venture capital transaction
Next: 4/3/2020: GPB Scientific venture capital transaction

 

Share this article

 


About Our VC Transactions Data

We do our best to report on every notable VC transaction. VC transactions reported here are derived from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary